Health board's fragile services need urgent change
Hospital services across a Welsh health board could be reorganised because they are so fragile.
Hywel Dda health board has included critical care, stroke services, eye care and urology among those in need of urgent attention.
Among the options would be to halve the number of acute stroke units and centralise planned urology cases and eye care.
A number of options will be given to the public, though the health board said it would welcome alternative suggestions as there was no preferred option.
It is understood each option put forward would come with a cost implication, but would be less than the current rising costs.
First minister 'misses NHS waiting times promise'
Hospital's £3m new cancer unit officially opens
Man's plea to save stroke unit that helped him talk again
Hywel Dda said changes were needed "because of the risks to them being able to continue to offer safe, quality services or timely care".
The four main hospitals in the area, which covers Pembrokeshire, Carmarthenshire and Ceredigion, are Prince Philip in Llanelli, Glangwili in Carmarthen, Withybush in Haverfordwest and Bronglais in Aberystwyth.
The health board said clinical teams were spread across multiple sites, over a wide geographic area, and there is an "over-reliance on a small number of individuals".
The nine areas deemed most fragile are:
Critical care
Dermatology
Emergency general surgery
Endoscopy
Ophthalmology
Orthopaedics
Radiology
Stroke
Urology
Hayden Harres, 65, said his local hospital, Glangwili, was "very good" but he would not want people to have to travel further for care.
"Distance is one factor, I think, especially for elderly people. If they have to travel further I don't think the care is better. I have every faith that the local hospital can provide the care that we need," he said.
Shadeen Lacaman, 27, from Haverfordwest, added she would support changes "as long as it's not too far from where you live".
The health board is not alone in facing challenges of reducing waiting times for treatment.
At a time when parts of Wales still have patients waiting longer than two years for care, it has removed those waits entirely, but still has more than 12,000 waiting longer than one year.
Staffing issues have improved predominantly due to the recruitment of international nurses, taking band five vacancies down from 280 whole-time equivalent to just 18.
The health board said that had substantially reduced its agency spend, but vacancies remained in other areas of its workforce.
Plans to update services were first drawn up in 2018 and while the pandemic increased demand, Hywel Dda has also had to contend with significant capital costs associated with issues around reinforced autoclaved aerated concrete (Raac) at Withybush Hospital.
A new hospital is planned for the area, but will not be built for at least 10 years after delays as well as the impact of inflation on construction costs.
Since the pandemic, there has also been an increased emphasis on regional working among health boards in Wales, meaning pressures can be spread across regions, though that also creates fresh logistical challenges.
Meanwhile backlog maintenance costs for an ageing estate continuing to rise, meaning doing nothing is not an option.
A previous report stated maintenance costs had increased from £60m to £255m since 2018, with £42m categorised as "high risk".
Glangwili and Withybush have the "most significant backlogs" at £90m and £72m respectively.
Any changes would be closely inspected by patients who are likely to face longer travel times for some services as a consequence, though the plans also include expansion in some areas and a greater role for primary and community services.
A public consultation on the options will be held over the summer with final plans expected to be put to the board by November.
Mark Henwood, executive medical director of the health board, said the reasons for the changes include difficulties in staffing services across all hospitals and the challenge of getting back to the same levels of treatments that were being delivered before the Covid pandemic.
Mr Henwood added: "Basically, we believe we're not delivering the highest standards of care to our patients."
He said: "These are not pre-determined options. We are going out to consult with our public about the services and to listen to their views about the services and if they identify options then of course we will consider those.
"No staff will lose their jobs during this process.
"This is not about saving money. This is about delivering the highest quality care to our patients."
Eiry Edmunds, deputy medical director, said clinicians are "anxious for progress and for change" and Senthil Kumar, the lead consultant for stroke services said changes are needed to improve standards of care in a health board where its geography is one of the "biggest issues".
The health board said: "Our 2024-25 end of year deficit was £24.1m, subject to audit.
"In previous years, spend was higher as a result of challenges faced during and following the Covid-19 pandemic, together with significant inflationary pressures.
"Focused effort by our teams, including reduced use of agency staff in the last financial year, and additional funding from Welsh government, has led to an improvement in our deficit position."
Nurse pay 'lagging behind' public sector, union says
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
an hour ago
- CNN
Dozens in northeast England report symptoms of potentially deadly botulism after getting Botox
Health officials in the UK are investigating reports of dozens of people suffering from a potentially life-threatening condition following Botox procedures in northeastern England, as well as allegations of the illegal sale of Botox-like products. The local trust of the UK's National Health Service (NHS) in the county of Durham put out an alert on June 13 about several people seeking medical attention after having adverse reactions to cosmetic procedures involving Botox. Since the incident first came to light last week, 28 individuals have reported symptoms of botulism after receiving cosmetic procedures, the UK Health and Security Agency (UKHSA) told CNN in a statement Friday. Botulism is a life-threatening condition caused by toxins made by Clostridium botulinum bacteria that attack the nervous system and cause paralysis. 'These toxins (but not the bacteria) are the active ingredient in Botox and similar products,' Dr. Joanne Darke, a consultant in health protection at the UKHSA, said in the statement, adding that it is 'important to go to a licensed practitioner.' Iatrogenic botulism is a type of botulism that occurs when too much of the cosmetic form, Botox, is injected into a muscle. Botox is a leading cosmetic treatment for wrinkles, as well as for medical conditions such as migraines and excessive sweating. The UKHSA said the reactions reported have included symptoms of severe drooping of the upper eyelids, double vision, difficulty swallowing, slurred speech and lethargy. Other symptoms of botulism can include facial muscle weakness. Botulism requires immediate medical attention and is fatal in 5-10% of cases, according to the NHS website. While most people make a full recovery with treatment, which typically involves getting injections with antitoxins, without quick care, paralysis can spread to muscles used to control breathing. While investigations into the cause of the cases are ongoing, the UKHSA said that 'evidence so far does not suggest that the product used has been contaminated. Symptoms are being reported a few days up to four weeks after injection.' 'The practitioners associated with most of the reported cases are no longer carrying out these procedures,' said Dr. Simon Howard, a consultant in health protection at the UKHSA, in the statement. 'However, that does not mean that we may not see more cases as symptoms can take up to four weeks to develop although we are now seeing the number of cases coming forward decreasing which is encouraging news,' he continued. Howard advised people to ensure they take precautions when seeking aesthetic procedures and advised anyone with symptoms to seek medical attention. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) told CNN Friday that it is investigating 'allegations surrounding the illegal sale and supply of Botox-type products in the North-East, and want to reassure the public that we take such claims very seriously.' The agency encouraged people in the UK who believe they have had side effects from medicine or received falsified stock to report it to its Yellow Card program. 'Our Criminal Enforcement Unit works hard to identify those involved in the illegal trade in medicines and takes robust enforcement action where necessary. This can include criminal prosecution,' Dr. Alison Cave, chief safety officer at MHRA, said in the statement. 'Botulinum toxin (Botox) is a prescription-only medicine and should only be available in the UK under the supervision of a doctor or other qualified healthcare professional,' she continued. In the United States, a growing cluster of botulism cases linked to cosmetic injections was reported in Massachusetts earlier this month. The state's Department of Health said it was investigating 10 cases of suspected iatrogenic botulism all associated with Botox procedures performed at one spa, Rodrigo Beauty.
Medscape
2 hours ago
- Medscape
ICU Skin Decolonisation May Raise Resistant Infections
Universal skin decolonisation of patients admitted to intensive care units (ICU) may not improve infection control. New research led by the University of Aberdeen indicated that it might increase meticillin-resistant Staphylococcus epidermidis (MRSE) bloodstream infections in vulnerable patients. Hospital-associated infections cause significant morbidity and mortality, with critically ill patients in ICUs at particularly high risk. Surveillance figures from English ICUs show an ICU-associated bloodstream infection rate of 3.5 per 1000 bed-days for stays of two nights or more in the year to March 2024. Over 25% of patients with these infections die within 30 days. Reasons for the increased infection rate in ICUs include high antibiotic use leading to significant skin flora colonisation by resistant bacteria. Invasive procedures including indwelling catheters and the insertion of intravascular devices are independently associated with meticillin-resistant Staphylococcus aureus (MRSA) colonisation and infection. Need for a New Infection Control Approach Decolonisation protocols were introduced in the 1990s to curb rising nosocomial MRSA infections due to MRSA. Nationwide infection control programmes since the mid-2000s led to sharp declines in MRSA rates in NHS hospitals over the next decade. One UK-wide study in ICU patients between 2007 and 2016 showed a 78% decrease in bloodstream infections overall and a 97% reduction in MRSA bloodstream infections. However, data from the National Institute for Health and Care Research show this decline plateaued after 2012. Rates have subsequently been largely static, suggesting the need for a new approach. Routine ICU decolonisation typically involves chlorhexidine skin disinfection combined with nasal mupirocin. The Aberdeen team noted conflicting evidence on chlorhexidine's effectiveness. They also raised concerns that biocide skin and mucous membrane decolonisation might lead to reduced susceptibility to chlorhexidine and selection for multidrug-resistant pathogens. Study Compares Universal and Targeted Decolonisation The researchers compared universal versus targeted skin and nasal decolonisation in ICU patients at two Scottish hospitals in adjacent health boards with different protocols. The study included patients aged 16 years and over admitted between 1 July 2009 and 28 Feb 2022. One hospital switched from universal decolonisation of all admissions to targeting only MRSA carriers from 1 February 2019. The other hospital used targeted decolonisation throughout. The researchers analysed rates of S. epidermidis bloodstream infections and tested MRSE and chlorhexidine susceptibility. Results Show Benefits in Reducing Resistant Infections The results, published in The Lancet Microbe , showed that S epidermidis was identified in 334 (45%) of 735 bloodstream infections in the hospital that de-escalated decolonisation. Of these, 197 occurred before de-escalation. Overall, bloodstream infection rates did not increase after de-escalation. However, MRSE infections declined significantly after the switch – from 10.4 to 4.3 cases per 1000 occupied bed days. The probability of MRSE among infections fell from 89.2% to 56.7%. By contrast, the control hospital reported 167 (60%) S. epidermidis bloodstream infections among 278 total, with no significant changes in infection rates or MRSE incidence. Genetic analyses revealed de-escalation was linked to fewer bloodstream infections caused by multidrug-resistant S. epidermidis strains. There was reduced carriage of mobile genetic elements and genes related to multidrug resistance and biofilm production. Balancing Benefits and Risks "In ICU settings with low MRSA incidence, the benefits of universal decolonisation should be balanced against the risks of selecting MRSE sequence types adapted for invasive and device-associated infection," the researchers concluded. Professor Karolin Hijazi, chair in oral and maxillofacial medicine at the University of Aberdeen and study lead, commented in a press release: "This research essentially demonstrates that the excess use of disinfectants in universal decolonisation offered no advantage in terms of control of serious blood infections in a low MRSA ICU setting, but instead caused the unintended rise of MRSE bloodstream infections." Implications for Infection Control Policy The authors recommended that hospitals consider the "unintended harms of universal decolonisation", especially given the global rise of antimicrobial resistance. Hijazi added that such practices increase resistance risks and costs without added benefit in low-MRSA settings. The findings should inform standardised national guidelines for effective and safe patient decolonisation, in line with the government's 5-year action plan for antimicrobial resistance, the researchers said. They described the emergence and spread of antimicrobial resistance as a 'silent pandemic' and stressed that reducing unnecessary decolonisation could help contain resistance and reduce costs.
CNN
2 hours ago
- CNN
Dozens in northeast England report symptoms of potentially deadly botulism after getting Botox
Health officials in the UK are investigating reports of dozens of people suffering from a potentially life-threatening condition following Botox procedures in northeastern England, as well as allegations of the illegal sale of Botox-like products. The local trust of the UK's National Health Service (NHS) in the county of Durham put out an alert on June 13 about several people seeking medical attention after having adverse reactions to cosmetic procedures involving Botox. Since the incident first came to light last week, 28 individuals have reported symptoms of botulism after receiving cosmetic procedures, the UK Health and Security Agency (UKHSA) told CNN in a statement Friday. Botulism is a life-threatening condition caused by toxins made by Clostridium botulinum bacteria that attack the nervous system and cause paralysis. 'These toxins (but not the bacteria) are the active ingredient in Botox and similar products,' Dr. Joanne Darke, a consultant in health protection at the UKHSA, said in the statement, adding that it is 'important to go to a licensed practitioner.' Iatrogenic botulism is a type of botulism that occurs when too much of the cosmetic form, Botox, is injected into a muscle. Botox is a leading cosmetic treatment for wrinkles, as well as for medical conditions such as migraines and excessive sweating. The UKHSA said the reactions reported have included symptoms of severe drooping of the upper eyelids, double vision, difficulty swallowing, slurred speech and lethargy. Other symptoms of botulism can include facial muscle weakness. Botulism requires immediate medical attention and is fatal in 5-10% of cases, according to the NHS website. While most people make a full recovery with treatment, which typically involves getting injections with antitoxins, without quick care, paralysis can spread to muscles used to control breathing. While investigations into the cause of the cases are ongoing, the UKHSA said that 'evidence so far does not suggest that the product used has been contaminated. Symptoms are being reported a few days up to four weeks after injection.' 'The practitioners associated with most of the reported cases are no longer carrying out these procedures,' said Dr. Simon Howard, a consultant in health protection at the UKHSA, in the statement. 'However, that does not mean that we may not see more cases as symptoms can take up to four weeks to develop although we are now seeing the number of cases coming forward decreasing which is encouraging news,' he continued. Howard advised people to ensure they take precautions when seeking aesthetic procedures and advised anyone with symptoms to seek medical attention. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) told CNN Friday that it is investigating 'allegations surrounding the illegal sale and supply of Botox-type products in the North-East, and want to reassure the public that we take such claims very seriously.' The agency encouraged people in the UK who believe they have had side effects from medicine or received falsified stock to report it to its Yellow Card program. 'Our Criminal Enforcement Unit works hard to identify those involved in the illegal trade in medicines and takes robust enforcement action where necessary. This can include criminal prosecution,' Dr. Alison Cave, chief safety officer at MHRA, said in the statement. 'Botulinum toxin (Botox) is a prescription-only medicine and should only be available in the UK under the supervision of a doctor or other qualified healthcare professional,' she continued. In the United States, a growing cluster of botulism cases linked to cosmetic injections was reported in Massachusetts earlier this month. The state's Department of Health said it was investigating 10 cases of suspected iatrogenic botulism all associated with Botox procedures performed at one spa, Rodrigo Beauty.
